Böblingen, March 2026 – Wörwag Pharma has reached an important milestone in the protection of its intellectual property: The European Patent Office (EPO) has granted European patent EP3679924B1 for ReDia®. The patent officially entered into force on 17 December 2025, strengthening the protection of the underlying innovation across Europe.
Wörwag Pharma strengthens European patent protection for ReDia®
The patent was transferred to Wörwag Pharma as part of the acquisition of ReDia® and was still pending at the time of the transaction. Following the acquisition, the focus was on strategically continuing the ongoing process, making the necessary decisions, and ensuring that the patent was granted and validated in the European markets most relevant to Wörwag Pharma.
The result of this strategic approach is a significantly expanded scope of protection. While the patent previously covered eleven European countries, ReDia® is now protected in 25 countries across Europe, including the company’s key core markets. This broader geographical coverage strengthens Wörwag Pharma’s position in the European market environment and creates additional strategic flexibility for the future.
This targeted approach not only secured the value of the patent but significantly enhanced it. Patents are a central element of Wörwag Pharma’s innovation and competitiveness strategy. They protect technological developments, provide legal certainty and support long term positioning in the respective markets. The successful integration of the ReDia® patent demonstrates how intellectual property can be systematically developed and embedded into a broader IP strategy, including in the context of acquisitions.
Innovation remains a continuous process. Wörwag Pharma continuously evaluates new ideas and developments with regard to their patentability in order to secure innovative products at an early stage and position them for long term success.
About ReDia®
ReDia® is a fiber‑based product from Wörwag Pharma’s portfolio in the field of metabolic health. As part of the acquisition, the associated intellectual property was also transferred and strategically further developed. The newly granted patent extension underscores the product’s long‑term relevance within the company’s overall strategy.
Further information about ReDia® can be found on our website: www.woerwagpharma.de